Kyverna Therapeutics Inc. (KYTX), which debuted on the Nasdaq as recently as February of this year, has since lost more than 20% of its stock value.
The company's lead program is KYV-101, an autologous CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) product candidate for use in B cell-driven autoimmune diseases such as lupus nephritis, systemic sclerosis, and inflammatory myopathies.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com